Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Can someone explain please

<< Previous

Bullboard Posts

Next >>

Comment by IrishCanuckon Aug 13, 2021 2:14pm

303 Views

Post# 33701599

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Can someone explain please

I'd say there are multiple ways to acheive success, and I'd put our chances at greater than 50% because we've already gotten huge data sets in Phase 2, AME and animal studies. We have a great scientific and medical team. I trust whatever they design because they have the rationale right in front of them. You and I can only speculate

MrMugsy wrote:

PlaySafe wrote: @IrishCanuck -- just speculation but if Antibe does another Phase 2 at 75mg I would think that they would want to run the trial on say 300+ participants over 4 weeks to improve the chances of efficacy statistical significance over placebo....do you agree? Of do you think that we only need to go for two weeks?

I can only say that one analyst is speculating at a number much less than your 300 ... but that's just an analyst. Then again, they are closer to the company than we are and we've already done a P2 ... so smaller might make sense.

Really, we need to wait for September's update.
If 75 mg looks promising then we will go in one direction.
If 75 mg doesn't look promising, we likely get a very different plan.
IMO.